Project Grant R01CA272854
Award Date
8/1/22
Completion Date
7/31/27
Dollars Obligated
$371K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45221, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $485,558 over 5 years to The General Hospital Corporation (Massachusetts General Hospital) for a study on a novel glutathione-dependent metabolic pathway that drives metastatic outgrowth in pancreatic cancer. The research aims to molecularly characterize key factors involved in this pathway, with the potential to develop new diagnostic markers and therapeutic strategies for treating...
This federal Project Grant award of $436,431 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to target metabolic crosstalk in pancreatic ductal adenocarcinoma (PDA). The University of California, Irvine is the prime awardee, conducting fundamental investigations into mechanisms that maintain cancer cell heterogeneity and metabolic symbiosis in PDA tumors. The research aims to identify oncogenic and stress pathways that can be targeted to...
This $125,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to investigate the role of cellular metabolism in regulating precancerous stages of pancreatic cancer development.
The key products and services to be delivered through this 2-year grant include: 1) Mechanistic studies on how the metabolic enzyme ME1 contributes to acinar-to-ductal metaplasia (ADM) and...
The Johns Hopkins University was awarded a $431,561 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research aimed at elucidating the role of the HMGA1 chromatin regulator in pancreatic ductal adenocarcinoma (PDAC) progression and the tumor microenvironment (TME). The research project seeks to precisely define HMGA1-dependent mechanisms in PDAC tumor progression using mouse models and primary human tumors, as well as...
This $698,008 federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research conducted by The Trustees of the University of Pennsylvania to investigate the relationship between branched-chain amino acid metabolism and histone propionylation, a chromatin modification associated with gene expression, in pancreatic ductal adenocarcinoma (PDA). The project aims to elucidate the mechanisms by which nuclear-localized branched-chain...
This $166,037 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to determine the impact of CDK4/6 inhibition on the progression of intraductal papillary mucinous neoplasms (IPMN), a precursor to pancreatic cancer. The research will be conducted by the University of California, San Diego, leveraging genetically modified mouse models and patient-derived xenograft models to analyze tumor progression, survival, and the tumor...
This $636,046 Project Grant awarded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to Weill Medical College of Cornell University aims to define the role of different KRAS oncogene variants in pancreatic ductal adenocarcinoma (PDAC) progression and identify therapeutic vulnerabilities.
The research will (1) decipher how cell lineage impacts the neoplastic transformation and molecular evolution of epithelial cells in KRAS G12R and G12V mutant PDAC, (2) define the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The Institute for Cancer Research to investigate the role of the protein Anoctamin 6 (ANO6) in disrupting lipid transfer between cancer-associated fibroblasts and pancreatic cancer cells. The $642,755 award, which commenced on March 7, 2025 and is scheduled for completion by February 28, 2030, aims to:
Delineate the signaling mechanisms by which cancer cells induce...
The National Cancer Institute (NCI) awarded The Johns Hopkins University a $432,889 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct innovative research on reversing pancreatic cancer-induced cachexia. The five-year project aims to apply molecular and functional imaging capabilities, as well as theranostic nanoparticle technologies, to target the glutamine/glutamate axis and disrupt glutamine metabolism in preclinical pancreatic cancer models....
This $667,118 five-year Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research by the University of California, San Francisco (UCSF) to identify and target key lysosomal proteins that enable the growth and metastasis of pancreatic ductal adenocarcinoma (PDAC), an incurable form of pancreatic cancer.
The primary objectives are to: 1) explore the role of the lysosomal hydrolase PLBD1 in supporting PDAC cell metabolism by removing...